

Yael Steinberg-Silman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3354909/publications.pdf>

Version: 2024-02-01

9
papers

1,173
citations

1162367

8
h-index

1473754

9
g-index

9
all docs

9
docs citations

9
times ranked

1691
citing authors

#	ARTICLE	IF	CITATIONS
1	Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. <i>Science</i> , 2021, 371, 602-609.	6.0	784
2	Isolated autoimmune adrenocorticotropic hormone deficiency: From a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors. <i>Autoimmunity Reviews</i> , 2020, 19, 102454.	2.5	47
3	Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma. <i>Cancers</i> , 2020, 12, 2329.	1.7	45
4	Vemurafenib-induced DRESS/DIHS resulting in spontaneous melanoma regression: an immunological reaction shedding new light on melanoma treatment?. <i>International Journal of Dermatology</i> , 2020, 59, e139-e141.	0.5	4
5	Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2019, 24, 640-647.	1.9	32
6	Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients. <i>European Journal of Cancer</i> , 2019, 108, 61-68.	1.3	48
7	Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. <i>Autoimmunity Reviews</i> , 2018, 17, 284-289.	2.5	149
8	Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case-Control Study. <i>Cancer Immunology Research</i> , 2018, 6, 1453-1458.	1.6	35
9	Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600 mutant metastatic melanoma. <i>European Journal of Cancer</i> , 2018, 101, 229-235.	1.3	29